Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19

W Larry Gluck, Sean P Callahan, Robert A Brevetta, Antine E Stenbit, Wesley M Smith, Julie C Martin, Anna V Blenda, Sergio Arce, W Jeffery Edenfield, W Larry Gluck, Sean P Callahan, Robert A Brevetta, Antine E Stenbit, Wesley M Smith, Julie C Martin, Anna V Blenda, Sergio Arce, W Jeffery Edenfield

Abstract

Objectives: Cytokine release syndrome (CRS) is a potentially severe complication of COVID-19 most commonly resulting in respiratory failure. This ten-patient study was designed to determine the efficacy of therapeutic plasma exchange (TPE) in improving oxygenation and in reducing the cytokine load in a critically ill subset of patients.

Methods: Five single volume plasma exchanges over eight days within a 14-day study period. In mechanically ventilated patients, oxygenation was measured via the PaO2/FiO2 (P/F) ratio and the oxygenation index (OI) daily for 14 days. Supplemental oxygen requirements were tracked daily for non-ventilated patients.

Results: Non-ventilated patients were liberated from supplemental oxygen after TPE. The response was rapid with an 87% average reduction in oxygenation requirements following and average time to return to room air of 5.25 days. All mechanically ventilated patients demonstrated improvement in oxygenation with a 78% average improvement in the P/F ratio and a 43% improvement in OI. C-reactive protein (CRP) and serum levels of IL-6, IL-8, IL-10, TNFα, IFNγ and GM-CSF, were measured daily with immediate post TPE levels drawn on days 1, 2, 4, 6 and 8. All patients demonstrated significant reductions in CRP, IL-6, IL-10 and TNFα.

Conclusions: In the majority of patients with Penn class 3 and 4 CRS complicating COVID-19, TPE demonstrated a prompt improvement in oxygenation and reduction in cytokine load without compromising patient safety. As this pilot study was envisioned to be hypothesis generating, expanded trials using TPE alone and in conjunction with novel pharmacologic agents are warranted.

Registration: ClinicalTrials.gov NCT04374149.

Keywords: COVID-19; Cytokine release syndrome; Oxygenation; Respiratory failure; Therapeutic benefit; Therapeutic plasma exchange.

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: W. Jeffery Edenfield serves as a consultant for Chimerix, Inc., unrelated to the submitted work. The remaining authors have disclosed that they do not have any conflicts of interest.

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Fig. 1
Fig. 1
Two-sample Median Comparisons for CRP and Cytokine Levels. The median of CRP and cytokine levels was compared in all ten patients following the second and fifth (final) plasma exchange and at day 14. a Non-cardiac (inflammatory) CRP reference range. b Cytokine levels represent average concentrations + standard deviation [Kim et al. J TranslMed 9,113 (2011) https://doi.org/10.1186/1479-5876-9-113].

References

    1. Zhou P., Yang X., Wang X., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
    1. Novel Coronavirus Situation Report-2. World Health Organization; Geneva: January 2020.
    1. Transmission of SARS-CoV-2: Implications for Infection Prevention Precautions. World Health Organization; Geneva: July 2020.
    1. Padmanabhan A., Connelly-Smith L., Aqui N., et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J. Chromatogr., A. 2019;34(3):167–354.
    1. Busund R., Koukline V., Utrobin U., et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002;28:1434–1439.
    1. Rimmer E., Houston B.L., Kumar A., et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock; a systematic review and meta-analysis. Crit. Care. 2014;18(6):699.
    1. Tesar V., Jelinkova E., Masek Z., et al. The effect of plasmapheresis on cytokine storm levels and adhesion molecules in ANCA-positive renal vasculitis. Cas. Lek. Cesk. 1997;136(20):627–632.
    1. Lyu R.K., Chen W.H., Hsieh S.T. Plasma exchange versus double filtration plasmapheresis in the treatment of Gillain-Barre syndrome. Ther. Apher. 2002;6(2):163–166.
    1. Conti P., Ronconi G., Caraffa A., et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19: anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents. 2020;34(2)
    1. Huang C., Wang Y., Ki X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
    1. Mehta P., McAuley D.F., Brown M., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;295(10229):1033–1034.
    1. Xiao X., Xiaoyuan H., Li Q., et al. Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: a case report. Clin. Canc. Res. January 1 2019;(25):29–34. doi: 10.1158/1078-0432.CCR-18-1379. 2019, 1.
    1. Patel P., Nandwani V., Vanchiere J., et al. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A-An associated respiratory failure and hemodynamic shock. Pediatr. Crit. Care Med. 2011;12:e87–e89.
    1. Shi H., Zhou C., He P., et al. Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19. Int. J. Antimicrob. Agents. 2020;56(2):105974. doi: 10.1016/j.ijantimicag.2020.105974.
    1. Tabibi S., Tabibi T., Conic R.R.Z., et al. Therapeutic plasma exchange: a potential management strategy for critically ill COVID-19 patients. J. Intensive Care Med. 2020;35(9):827–835. doi: 10.1177/0885066620940259.
    1. Khamis F., Al-Zakwani I., Al Hashmi S., et al. Therapeutic plasma exchange in adults with severe COVID-19 infection [published online ahead of print, 2020 jun 22] Int. J. Infect. Dis. 2020;S1201–9712(20) doi: 10.1016/j.ijid.2020.06.064. 30499-9.
    1. Morath C., Weigand M.A., Zeier M., et al. Plasma exchange in critically ill COVID-19 patients. Crit. Care. 2020;24(1):481. doi: 10.1186/s13054-020-03171-3. Published 2020 Aug 4.
    1. Stahl K., Bode C., David S. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19. Crit. Care. 2020;24(1):363. doi: 10.1186/s13054-020-03070-7. Published 2020 Jun 18.
    1. Cantanzaro M., Fagiani F., Racchi M., et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target Ther. 2020;5:84. doi: 10.1038/s41392-020-0191-1.
    1. Auld S.C., Caridi-Scheible M., Blum J.M., et al. 2019. ICU and Ventilator Mortality Among Critically Ill Adults with Coronavirus Disease. Crit Care Med 2020, [published online ahead of print, 2020 May 26]
    1. Porter D., Frey N., Wood P., et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J. Hematol. Oncol. 2018;11:35.
    1. Magnetic Luminex Performance Assay. Minneapolis, MN: R&D Systems, Inc.
    1. Zhang C., Wu Z., Li J.-W., et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int. J. Antimicrob. Agents. 2020 May;55(5):105954. [published online ahead of print, 2020 Mar 29]
    1. Sinha P., Matthay M.A., Calfee C.S. Is a “cytokine storm” relevant to COVID-19? JAMA Int. Med. 2020;180(9):1152–1154. doi: 10.1001/jamainternmed.2020.3313.
    1. Beigel J.H., Tomashek K.M., Dodd L.E., et al. Remdesivir for the treatment of covid-19 - preliminary report. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2007764. NEJMoa2007764, [published online ahead of print, 2020 May 22]
    1. Price C.C., Altice F.L., Shyr Y., et al. Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. 2020 doi: 10.1016/j.chest.2020.06.006.
    1. Seeley E., McAuley D.F., Eisner M., et al. Predictors of mortality in acute lung injury during the era of lung protective ventilation. Thorax. 2008;63:994–998.
    1. Balzer F., Menk M., Ziegler J., et al. Predictors of survival in critically ill patients with acute respiratory distress syndrome (ARDS): an observational study. BMC Anesthesiol. 2016;16:108.
    1. Monchi M., Bellenfant F., Cariou A., et al. Early predictive factors of survival in the acute respiratory distress syndrome. A multivariate analysis. Am. J. Respir. Crit. Care Med. 1998;158:1076–1081.
    1. Villar J., Pérez-Méndez L., López J., et al. An early PEEP/FIO2 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2007;176(8):795–804.
    1. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]
    1. Goshua G., Pine A.B., Meizlish M.L., et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–e582. doi: 10.1016/S2352-3026(20)30216-7.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj